Drug recall · August 12, 2026
Mirabegron Extended-Release Tablets recall
Why: CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Mirabegron Extended-Release Tablets, 25 mg, 30-count bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Matoda, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1159-3.
- Lots / codes
Lot # E408618, Expiry: 11/30/2026, NDC #: 70710-1159-3
- Company
- Zydus Pharmaceuticals (USA) Inc, Pennington, NJ
- Distribution
- Nationwide in the USA
- Initiated
- August 5, 2026 · Voluntary: Firm initiated
- Classified
- August 7, 2026
- Reported
- August 12, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Mirabegron
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.